3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
6
Nivolumab
3
Gemcitabine
3
Cisplatin
3
Carboplatin
3
brigimadlin
2
Ramucirumab
2
Fluorouracil
2
Docetaxel
2
Cetuximab
2
tucatinib
1
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
pertuzumab
1
milademetan
1
larotrectinib
1
futibatinib
1
durvalumab
1
cemiplimab
1
adagrasib
1
Trastuzumab
1
TAS-116
1
Ritonavir
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Omacor
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Clinical Trials, Phase II as Topic
×
Thoracic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled